We conducted a phase 1/2 trial of high-dose 90 Y-ibritumomab tiuxetan in combination with
high-dose etoposide (VP-16) 40 to 60 mg/kg (day -4) and cyclophosphamide 100 mg/kg (…

Purpose This phase II trial evaluated the safety and efficacy of combining yttrium-90 (90Y)
ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (BEAM…

Purpose: Targeted systemic radiation therapy using radiolabeled antibodies results in tumor
doses sufficient to produce significant objective responses in the radiosensitive …

Purpose: The chimeric T84.66 (cT84.66) minibody is a novel engineered antibody construct
(V L -linker-V H -C H 3; 80 kDa) that demonstrates bivalent and high affinity (4 × 10 10 m −1 ) …

Chimeric T84.66 (cT84.66) is a genetically engineered human/murine chimeric IgG 1 with
high affinity and specificity to carcinoembryonic antigen (CEA). The purpose of this Phase I …

18 F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT)
is one of the most widely used imaging techniques to detect multiple myeloma (MM). …

Purpose/Objective: Previous radioimmunotherapy (RIT) clinical trials at this institution with
90 Y-labeled cT84.66 anti-CEA (carcinoembryonic antigen) evaluated the antibody …

Chimeric T84. 66 (cT84. 66) is a high-affinity (1.16 x 10 [11] M [-1]) IgG1 monoclonal
antibody (MAb) against carcinoembryonic antigen (CEA). This pilot trial evaluated the tumor-…

Allogeneic bone marrow transplant (BMT) recipients have many known risk factors for
developing decreased bone mineral density (BMD) after transplantation. We performed a …

High-risk relapsed or refractory (R/R) classical Hodgkin lymphoma (HL) is associated with
poor outcomes after conventional salvage therapy and autologous hematopoietic cell …